Eliglustat
- Generic Name
- Eliglustat
- Brand Names
- Cerdelga
- Drug Type
- Small Molecule
- Chemical Formula
- C23H36N2O4
- CAS Number
- 491833-29-5
- Unique Ingredient Identifier
- DR40J4WA67
- Background
Eliglustat is a glucosylceramide synthase inhibitor used for the long-term treatment of type 1 Gaucher disease. Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide. In patients with Gaucher disease, the accumulation of glucosylceramide leads to th...
- Indication
Eliglustat is a glucosylceramide synthase inhibitor indicated for the long-term treatment of type 1 Gaucher disease in adult patients who are CYP2D6 extensive metabolizers (EMs), intermediate metabolizers (IMs), or poor metabolizers (PMs) as detected by an FDA-cleared test. CYP2D6 ultra-rapid metabolizers may not achieve adequate eliglustat concentrations to...
- Associated Conditions
- Gaucher Disease, Type 1
- Associated Therapies
- -
A Study to Evaluate Pharmacokinetic Parameters and Safety of Eliglustat Absorption Through the Mouth
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 6
- Registration Number
- NCT06193304
- Locations
- 🇺🇸
Covance Clinical Researsh Unit, Evansville, Indiana, United States
A Study to Evaluate Pharmacokinetic Parameters of Eliglustat in Healthy Volunteers Who Are CYP2D6 Extensive or Poor Metabolizers
- First Posted Date
- 2024-01-03
- Last Posted Date
- 2024-01-10
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 18
- Registration Number
- NCT06188325
- Locations
- 🇺🇸
M.D.Covance Clinical Research Unit 1341 W, Dallas, Texas, United States
GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
- Conditions
- Interventions
- First Posted Date
- 2021-06-30
- Last Posted Date
- 2023-12-19
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 31
- Registration Number
- NCT04944888
- Locations
- 🇨🇳
Department of Biotherapeutic, Chinese PLA General Hospital, Beijing, China
Eliglustat on Gaucher Disease Type IIIB
- First Posted Date
- 2018-05-09
- Last Posted Date
- 2022-09-15
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 4
- Registration Number
- NCT03519646
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
A Study of the Effects of Renal Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 32
- Registration Number
- NCT02536937
- Locations
- 🇺🇸
Investigational Site Number 840004, Miami, Florida, United States
🇺🇸Investigational Site Number 840001, Knoxville, Tennessee, United States
🇺🇸Investigational Site Number 840002, St. Paul, Minnesota, United States
A Study of the Effects of Hepatic Impairment on the Pharmacokinetics and Tolerability of Eliglustat Tartrate
- First Posted Date
- 2015-09-01
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 24
- Registration Number
- NCT02536911
- Locations
- 🇺🇸
Investigational Site Number 840002, Miami, Florida, United States
🇺🇸Investigational Site Number 840001, Knoxville, Tennessee, United States
Taste Evaluation of Different Liquid Formulations With Eliglustat
- First Posted Date
- 2015-04-21
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 8
- Registration Number
- NCT02422654
- Locations
- 🇺🇸
Investigational Site Number 840001, Evansville, Indiana, United States
Study to Evaluate the Effect of Eliglustat on the Pharmacokinetics, Safety and Tolerability of Metoprolol in Healthy Adults
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2015-03-23
- Lead Sponsor
- Genzyme, a Sanofi Company
- Target Recruit Count
- 14
- Registration Number
- NCT01659944
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.